NLS Pharmaceutics' Shares Fall As Data From Narcolepsy Candidate Fails To Cheer Investors

NLS Pharmaceutics Ltd NLSP announced topline results from its Phase 2a trial evaluating its lead product candidate, Quilience (Mazindol ER), in narcolepsy.
The trial met its primary endpoint with high statistical significance.
Treatment with Quilience 3mg per day (NLS-2) resulted in a 7.1 point mean reduction from baseline in excessive daytime sleepiness (EDS) over the 4-week treatment period, compared to a 3.2 point reduction for placebo.
The two treatment groups separated early and consistently throughout the study, confirming Mazindol ER's rapid onset of action and durable benefit.
Quilience was well-tolerated, and no safety concerns were identified. No serious adverse events (SAEs) were reported. Regarding the reduction in cataplexy attacks in narcolepsy Type 1 patients (NT1), a key secondary endpoint, Quilience consistently outperformed placebo at all times.
NLS plans to release interim results from the OLE study before year-end and announce final results in the first quarter of 2023.
Price Action: NLSP shares are down 12.90% at $0.81 on the last check Tuesday.